Study: Curcumin and PREMENTRULE SIDDROM
Study: Curcumin and PREMENTRULE SIDDROM
Reference
Khayat S, Fanaei H, Kheirkhah M, Moghadam ZB, Kasaeian a, Javadimehr M. Curcumin alleviates the severity of the symptoms of premenstrual syndrome: a randomized, double -blind, placebo -controlled study. Supplement Ther Med . 2015; 23 (3): 318-324.
Design
randomized, double -blind, placebo -controlled study
participant
seventy students (18-34 years) lived in the dormitories of the Tehran University of Medical Sciences in 2013. They considered healthy, had a cycle of 21-35 days, were single, did not occupied any medication, did not consume alcohol, did not smoke tobacco and reported no stressful events in the previous three months.
inclusion criteria
The participants found a premenstrual syndrome (PMS) if they had at least 5 of the 19 PMS symptoms listed in the DMS-IV.
exclusion criteria
participants were excluded if they had side effects of medication, medication allergies, drug use, alcohol consumption, smoking, drug use disorders in the history, a disease diagnosed during the study during the study, undergrowth, or irregular bleeding events during the study.
instruments
The DMS IV-PMS symptom table was divided into mood, physical and behavioral symptoms. The participants rated each symptom as either missing, light, moderate or difficult regarding the daily activities for 2 cycles before they received either the placebo or treatment intervention. The PMS symptoms were assessed after the study of the study after the first, second and third menstrual cycle.
treatment
curcumin was obtained from Darou Pakhsh Pharma Company, Tehran, Iran. The placebo was brown sugar. Both were encapsulated in gelatin capsules by a handmade at the Faculty of Pharmacy at the University of Tehran. The Faculty of Pharmacy kept the code until the study.
The dose was 100 mg/12 h curcumin or placebo, administered 7 days before and up to 3 days after the menstrual bleeding is inserted.
results
of the originally 70 women 4 in placebo and 3 in curcumin did not complete the study. In the placebo group, 2, 1 received a medication/medication and a fourth suffered from menstrual discretion. In the curcumin group, 2 abused the curcumin capsules, and the third had menstrual regulators.
The demographic data before the study were similar in terms of mean value and standard deviation. The PMS scores for body, behavior, mood and the entirety of all symptoms were similar before the study in terms of mean value and standard deviation.
In the curcumin group, the physical, behavioral and mood-related PMS symptom values significantly decreased (all p <0.0001). In the placebo group, the middle physical PMS symptom score ( p = 0.0425) decreased, but the values for behavioral and mood symptoms did not change significantly ( p = 0.3544 and p = 0.4006). The overall score decreased significantly in the curcumin group ( p <0.0001), but not in the placebo group ( p = 0.58).
results
This study showed that curcumin in these women better reduced the PMS symptoms over 3 menstrual cycles based on the DMS IV criteria than placebo.
Study restrictions
The substance used in the study was identified as a curcumin, but its purity was not verified, and the presence or lack of frequently associated curcuminoids such as Demethoxycurcumin, Monodemethoxycurcumin, Dihydrocurcumin, Cyclocurcumin and Bisethoxycurcumin was not given. turmeric longa contains at least 8 curcuminoids, with curcumin itself out of 60 % of the total curcuminoid content.
The dose was 100 mg/12 hours, but it was not stated whether this was taken as individual or several capsules with or without food or at what time of day. It was reported that the curcumin capsules in smell, taste, shape, texture, color and size are the same as the placebo capsules made of brown sugar. This is questionable because curcumin is orange and has a clear color and a clear smell, while brown sugar is brown and also has a clear smell and a clear color. The dose of the placebo capsules was not given.
A curcumin dose of 100 mg/12 hours is unusually low in view of the concerns regarding its bioavailability. Most studies in humans have used doses of up to or 8 grams.
Comment
curcumin and the related bioflavonoids have shown anti -inflammatory effects and neurological effects. Curcumin also has antimicrobial, antihypertensive, antihyperlipidemic, antitumor, anti-cancer, antiphlogistic, antiabetical, anti-diabetical, anti-psoriasis, antithrombotic and anti-Ipatotoxic effects. Molecular weight and its polar structure enable him to penetrate the blood-brain barrier. 2 In animal experiments, the neurogenesis in adult hippocampus, gyrus dentatus, improve mice. prevents Alzheimer's disease. 4 In animal models, it protects against amygdaloid-induced seizures (rats), iron-induced epileptic seizures (mice) and electroshock-induced seizures (mice). It has shown positive effects in swimming stress and depression for enforced swimming stress and depression, reser-pin-induced depression and modulation of serotonin and dopamine. 4 It is also protective in animal models from TARDIVER DYSKINESIE.
In particular, curcumin inhibits the enzymes monoaminoxygenase (MAO) -a and Mao-B, which are also involved in the breakdown of noradrenaline, serotonin and dopamine. Curcumin increases the effect of fluoxetine (a selective serotonin reuptake inhibitor), bupropion (a dopamine reuptake inhibitor) and venlafaxin (a selective noradrenaline reuptake inhibitor). (TRIZYKLIKUM). 8 In the mouse, serotonin and dopamine were increased, but not Norepinephrin. Curcumin was blocked by p-chlorphenylalanine, a tryptophan hydroxylase inhibitor. 5-hydroxytrypta (5-HT) 1A/1b and 5-HT 2C receptors are involved in the antidepressant effect of curcumin.
A new mouse compulsory float test with rats and a tailbo used with mice, curcumin 50 mg/kg, curcumin 100 mg/kg, fluoxetine 20 mg/kg, curcumin 100 m/kg with fluoxetin 20 mg/kg and curcumin 100 MG/KG with iMipramin 15 mg/kg. 8 The curcumin extract used in this study consisted of at least 95 % of curcumin and contained other curcuminoids and essential oils that were intended to increase its retention and bio tapness to increase 7 times. The study showed that curcumin had a similar activity in mice and rats as fluoxetine and imipramine, but did not improve the activity of either of the two if it was administered in combination. Curcumin increased the neurogenesis during animal stress, probably via the hypothalamus hypophysen-adrenal axis and the high regulation of 5-HT 1A receptors.
curcumin was used in at least 4 recently carried out studies in humans in depression with 40 to 140 patients. Curcumin doses ranged from 500 mg/d to 1,000 mg/d; 1 study used 1,000 mg curcumin with 10 mg piperine. In a 5-week study with 40 older patients with major depression, the participants received either escitalopram (n = 19) or venlafaxine (n = 21) and placebo or curcumin. The curcumin group tended to a faster improvement, but this was not statistically significant. 9 A study with 56 patients with major depression received placebo or curcumin (1,000 mg/day) for 8 weeks. There was no significant difference at the end of the study. 10 An open study with a curcumin piperin combination (1,000 mg or 10 mg) In 140 patients with serious depressive disorder under antidepressants lasted 6 weeks. There were improvements in the Beck depression inventory and in the somatic and cognitive subscales, but not on other scales. 11 In a 6-week study, 60 patients with major depression (1,000 mg/day), fluoxetine (20 mg/day) or a combination. There were no significant differences between the groups. 12 In no these studies differ in the number and extent of the undesirable events between the curcumin and placebo or prescription medication group. The duration of the studies mentioned above is probably too short for the treatment of severe depressive disorder. The fact that animal studies showed that curcumin did not always increase the effect of antidepressants could also be a factor for the results mentioned above.
clinical implications
curcumin has a variety of neurological effects. These were detected in mice and rats. Curcumin also has neurological effects in humans, but the treatment of severe depressive disorder in moderate doses (500-1,000 mg/day) can exceed the skills of this herb. In a small PMS study, curcumin with 100 mg/12 h was more effective than placebo. Recommendations to dose curcumin and the ingredients turmeric longa Extracts for various psychological and psychiatric diseases still have to be fully clarified. Use of turmeric longa of naturopathic doctors in mental-emotional diseases requires attention for the individual patient, the botanical extract and the medication that the patient may take.
- Sandeep GK, Amit L., Vinay J., et al. Phytochemistry from Curcuma Longa - an overview. j pharmaceutical biomed sc i. 2010; 4 (01): 1-9.
- Kulkarni SK, Dhir p. 2010. An overview of curcumin in neurological diseases. Indian J. Pharm. Sci . 2010; 72 (2): 149-154.
- Shin Hi, Lee Jy, Son e, et al. Curcumin stimulates the proliferation of embryonic neural progenitor cells and neurogenesis in adult hippocampus. jbiolchem . 2008; 283: 14497-14505.
- Kulkaarni SK, BHUTANI MK, Bishnoi M. Antidepressant activity of curcumin: participation of serotonin and dopamine systems. Psychopharmacology . 2008; 201: 435-442.
- bishnoi M, Chopra K, Kulkarni SK. Protective effect of curcumin, the active ingredient of the turmeric ( turmeric longa ) in haloperidol-induced orofacial dyskinesia and associated behavioral, biochemical and neurochemical changes in the brain of rats. pharmacol biochem Behof . 2008; 88: 511-522.
- Kulkaarni SK, BHUTANI MK, Bishnoi M. Antidepressant activity of curcumin: participation of serotonin and dopamine systems. Psychopharmacology . 2008; 201: 435-442.
- Wang R, Li Yb, Li Yh, Xu Y, Wu HL, Li XJ. Curcumin protects against glutamate ecitototoxicity in cerebral cortical neurons of rats by increasing the mirror of the neurotrophic factor from the brain and activates TRKB. brain . 2008; 1210: 84-91.
- Sanmukhani J, Anovadiya A, Tripathi CB. Evaluation of the antidepressant effect of curcumin and its combination with fluoxetine and imipramine: an acute and chromical study. acta poloniae pharmaceutica - drug research . 2011; 68 (5): 769-775.
- j. Bergman, C. Miodownik, Y. Bersudsky, et al. Curcumin as an addition to antidepressant treatment: a randomized, double -blind, placebo -controlled pilot study. clin neuropharmacol . 2013; 36 (3): 73-77.
- Lopresti al, Maes M, Maker GL, et al. Curcumin for the treatment of severe depression: a randomized, double -blind, placebo -controlled study. j affect disord . 2014; 167: 368-375.
- Panahi Y, Badeli R, Karami Gr, Saebkar A. Investigation of the effectiveness of additional therapy with bio -availability -enhanced curcuminoids in major depression. Phytother-Res . 2015; 29 (1): 17-21.
- Sanmukhani J., Satodia V., Trivedi J., et al. Effectiveness and security of curcumin in major depression: a randomized controlled study. Phytother-Res . 2014; 28 (4): 579-585.